2023年度
1. Sakamaki I, Negoro E, Iwasaki H, Yamauchi T. Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follocular lymphoma patient treated with anti-CD20 antibodies. J Infect Chemother. 2024 Feb;30(2):147-149.
2. Onishi H, Yamamura O, Sakamaki I, Miyashita H, Iwasaki H. A Consideration of Relationship in COVID-19 Infection Status and Previously Reported Anti-SARS-CoV-2 Nucleocapsid (N). Asia Pac J Public Health. 2023 Nov 35(8):580-582.
3. Kobuchi T, Onishi H, Yamamura O, Sakamaki I, Iwasaki H, Hayashi H. Frequency and Risk Factors for Persistent and Concomitant Symptoms after Hospital Discharge for Coronavirus Disease 2019 in the Pre-omicron Period: An Exploratory Longitudinal Study. JMA J. 2023 Oct 16;6(4):437-447.
4. Yamamura O, Onishi H, Sakamaki I, Fujita R, Miyashita H, Iwasaki H. Infection rate among close contacts of patients with coronavirus disease in Japan: a descriptive study and literature review. Asian Biomed (Res Rev News). 2023 Oct 9;17(3):115-123.
5. Shimamoto Y, Sasaki H, Kasuno K, Watanabe Y, Sakashita S, Nishikawa K, Morita S, Nishikawa Y, Kobayasi M, Fukushima S, Enomoto S, Takahashi N, Hamano T, Sakamaki I, Iwasaki H, Iwano M. Posterior reversible encephalopathy syndrome (PRES) associated with SARS-CoV-2 infection in a patient under maintenance haemodialysis: a case report. BMC Nephrol. 2023 Sep 29;24(1):286.
6. Itoh K, Kabata D, Shigemi H, Hirota T, Sakamaki I, Tsutani H, Mitsuke Y, Iwasaki H. Evaluation of tetracycline and fluoroquinolone therapy against Japanese spotted fever: Analysis based on individual data from case report/series. Int J Antimicrob Agents. 2023 Aug 62(2):106895.
7. Asahi N, Sakamaki I, Hida Y, Torii K, Hashimoto N, Iwasaki H, Iwano M, Kimura H. Antibody level dynamics until after the third dose of COVID-19. Heliyon. 2023 Jun 22:e17477.
2022年度
1. Miyajima Y, Nagaoka K, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Kawamura T, Ueno A, Kawasuji H, Kawago K, Fukui Y, Sakamaki I, Yamamoto Y. Comparative Study of Three Commercial Blood (1→3)-β-D-glucan Detection Reagents for Invasive Mycosis. Med Mycol J. 2023;64(1):1-6.
2. Yoshida H, Makino A, Yamaguchi A, Matsuda S, Sakamaki I, Yoshimura H, Iwasaki H. Droplets adhesion to surgical masks during standard oral surgery. Jpn J Infect Dis. 2023 Jan 24;76(1):84-86.
3. Morioka H, Ohge H, Nagao M, Kato H, Kokado R, Yamada K, Yamada T, Shimono N, Nukui Y, Yoshihara S, Sakamaki I, Nosaka K, Kubo Y, Kawamura H, Fujikura Y, Kitaura T, Sunakawa M, Yagi T; Research Group of Japan Infection Prevention and Control Conference for National and Public University Hospitals. Apppropriateness of surgical antimicrobial prophylaxis in Japanese university hospitals. J Hosp Infect. 2022 Nov;129:189-197.
5. Onishi H, Yamamura O, Sakamaki I, Miyashita H, Iwasaki H. Can the Brinkman Index Predict the Need for Treatment in Patients With COVID-19? Asia Pac J Public Health.2022 Sep;34(6-7):692-694.
2021年度
1. Itoh K, Sakamaki I, Hirota T, Iwasaki H. Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study. J Infect Chemother. 2022 Jan;28(1):124-127.
2. Kawasuji H, Morinaga Y, Tani H, Yoshida Y, Taekgoshi Y, Kaneda M, Murai Y, Kimoto K, Ueno A, Miyajima Y, Fukui Y, Kimura M, Yamada H, Sakamaki I, Yamamoto Y. SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is storonglay associated with disease severity and mortality in patients with COVID-19. J Med Virol. 2022 Jan;94(1):147-153.
3. Sitafloxacin reduces tumor necrosis factor alpha (TNFα) converting enzyme (TACE) phosphorylation and activity to inhibit TNFα release from lipopolysaccharide-stimulated THP-1 cells. Sci Rep. 2021 Dec 17;11(1):24154.
4. Kawasuji H, Morinaga Y, Tani H, Kimura M, Yamada H, Yoshida Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Ueno A, Miyajima Y, Kawago K, Fukui Y, Sakamaki I, Yamamoto Y. Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19. Sci Rep. 2021 Aug 16;11(1):16535.
5. Fukui Y, Kawasuji H, Taekgoshi Y, Kaneda M, Murai Y, Kimoto K, Ueno A, Miyajima Y, Kawago K, Sakamaki I, Morinaga Y, Yamamoto Y. Investigation of nasopharyngeal viral load at discharge in patients with COVID-19. J Infect Chemother. 2021 Jul;27(7):1122-1125.
6. Ueno A, Kawasuji H, Miyajima Y, Fukui Y, Sakamaki I, Saito M, Yamashiro S, Morinaga Y, Oishi K, Yamamoto Y. Prolonged viral clearance of severe acute respiratory syndrome coronavirus 2 in the older aged population. J Infect Chemother. 2021 Jul;27(7):1119-1121.
7. Ueno A, Sakamaki I, Yamamoto Y. An elderly man with a locked jaw. Eur J Intern Med. 2021 Jun 10:S0953-6205(21)00166-7.
8. Murai Y, Kawasuji H, Takegoshi Y, Kaneda M, Kimoto K, Ueno A, Miyajima Y, Kawago K, Fukui Y, Ogami C, Sakamaki I, Tsuji Y, Morinaga Y, Yamamoto Y. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. Int J Infect Dis. 2021 May;106:33-35.
9. Kawasuji H, Tsuji Y, Ogami C, Kaneda M, Murai Y, Kimoto K, Ueno A, Miyajima Y, Fukui Y, Sakamaki I, Yamamoto Y. Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients. Antibiotics (Basel). 2021 Apr 26;10(5):496.
10. Kutsuna S, Asai Y, Yamamoto K, Shirano M, Konishi K, Asaoka T, Yamato M, Katsuragi Y, Yamamoto Y, Sahara T, Tamiya A, Nakamura-Uchiyama F, Sakamoto N, Kosaka A, Washino T, Hase R, Mito H, Kurita T, Shinohara K, Shimizu T, Kodama F, Nagasaka A, Ogawa T, Kasahara K, Yoshimura Y, Tachikawa N, Yokota K, Yuka Murai NS, Sakamaki I, Hasegawa C, Yoshimi Y, Toyoda K, Mitsuhashi T, Ohmagari N. Epidemiological trends of imported infectious diseases in Japan: Analysis of imported 2-year infectious disease registry data. J Infect Chemother. 2021 Apr;27(4):632-638.
